Showing 2121-2130 of 5964 results for "".
- Antihypertensive Drugs Linked to Increased Eczema in Elderlyhttps://practicaldermatology.com/news/antihypertensive-drugs-linked-increased-eczema-elderly/2463140/New research suggests that increased use of antihypertensive medications is associated with an increase in eczematous dermatitis. Researchers conducted a longitudinal cohort study in a population-based sample from primary care practices in The Health Improvement Network in the United Kingd
- Research IDs New Psoriasis Inflammation Pathwayhttps://practicaldermatology.com/news/research-ids-new-psoriasis-inflammation-pathway/2463125/Researchers from a recent study have identified a key biological pathway responsible for the inflammation seen in psoriasis, with potential implications for other inflammatory diseases like atopic dermatitis, allergic dermatitis, and hidradenitis suppurativa. The study, published in the j
- Roflumilast Foam Aligns with Industry Standards for Seborrheic Dermatitis Care: Studyhttps://practicaldermatology.com/news/roflumilast-foam-aligns-industry-standards-sd-care-study/2463119/A recent study published in the Journal of Clinical and Aesthetic Dermatology supports the approved formulation of roflumilast foam, noting that its alignment with beauty industry standards and exclusion of harmful ingredients is important for the confidence of practitioners using the tr
- International Cosmetic Surgery Patients Report Higher Seroma and Antibiotic Usehttps://practicaldermatology.com/news/international-cosmetic-surgery-patients-report-higher-seroma-and-antibiotic-use/2463111/International cosmetic surgery was associated with higher rates of antibiotic use and seroma formation, according to results from a new analysis. Researchers
- InnoCare Completes Patient Enrollment in Phase 2 Trial of ICP-488 for the Treatment of Psoriasishttps://practicaldermatology.com/news/innocare-completes-patient-enrollment-phase-2-trial-icp-488-treatment-psoriasis/2463108/InnoCare Pharma announced the completion of patient enrollment for the phase 2 clinical trial of ICP-488, a tyrosine kinase 2 (TYK2) JH2 allosteric inhibitor, for the treatment of psoriasis. The multicenter, randomized, double-blind, placebo-controlled phase 2 study aims to evaluate the e
- Pilot Study Supports Once-Daily Isotretinoin for Acne Treatmenthttps://practicaldermatology.com/news/pilot-study-supports-once-daily-isotretinoin-acne-treatment/2463088/Micronized isotretinoin administered once per day without food was effective and well-tolerated for the treatment of severe nodular acne, new study results indicate. Researchers for the pilot study focused on and evaluated a regimen of once-daily micronized isotretinoin (0.4 to 0.8 mg/kg/
- Oral HSP90 Inhibitor Gets Positive Feedback From FDAhttps://practicaldermatology.com/news/oral-hsp90-inhibitor-gets-positive-feedback-fda/2463023/A first-in-class oral drug candidate for the treatment of hidradenitis suppurativa (HS) received positive feedback from a pre-Investigational New Drug meeting with the US Food and Drug Administration (FDA), according to a press release. MC2 Therapeutics, a commercial stage biotech company
- Novel Species and Drug Resistance Found in Skin Infectionshttps://practicaldermatology.com/news/novel-species-and-drug-resistance-found-skin-infections/2463021/A recent study highlighted growing concerns within the dermatological community regarding an increase in treatment-resistant fungal strains. Researchers from The University of Texas Health Science Center at San Antonio focused their investigation on dermatophytes, a group of fungi respons
- Survey Highlights Increased Risk of Sunburn and Skin Cancer Among Outdoor Workershttps://practicaldermatology.com/news/survey-highlights-increased-risk-sunburn-and-skin-cancer-among-outdoor-workers/2463018/A recent survey conducted by the American Academy of Dermatology (AAD) highlighted the heightened risk of sunburn and skin cancer faced by outdoor workers in the United States. The survey, according to a press release, included responses from more than 1,000 U.S. adults and emphasized the
- Atopic Dermatitis Not Linked with Increased Risk for Venous Thromboembolismhttps://practicaldermatology.com/news/atopic-dermatitis-not-linked-increased-risk-venous-thromboembolism/2462969/A recent retrospective cohort study published in the latest issue of the Journal of the American Academy of Dermatology showed that venous thromboembolism (VTE) risk among patients with atopic dermatitis (AD) was lower than that of other immune-mediated inflammatory diseases (IMIDs).